Ladadee
|
5/19/2020 9:09:46 AM
A tale of 2 drugs: Lives sacrificed on the altar of money & power..
"Money over medical wisdom, and politics above patients: two viruses more lethal than COVID-19."
https://www.wnd.com/2020/05/tale-2-drugs-lives-sacrificed-altar-money-power/
In decades of widespread use, HCQ has an impressive safety record. Irregular heart rhythm or damage to the retina occur rarely, usually with high doses used long term. The FDA shows only 62 cardiac deaths attributed to HCQ out of more than 50 million prescriptions, or 0.000124% (1.2 out of each 1 million Rx). Rheumatology guidelines for lupus and rheumatoid arthritis do not even require baseline electrocardiograms before prescribing HCQ, since the risk is minimal.
Approximately $70 million in U.S. taxpayer funding began Gilead's partnership with the U.S. Army, Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) to develop remdesivir. Initially for treating Ebola, it failed to show benefit and was shelved. If remdesivir is used to treat COVID-19, Gilead shareholders, not the taxpayers, will profit.
Early results of the first clinical trial of remdesivir against placebo in coronavirus showed modest benefits, according to The New York Times. Surviving patients given remdesivir were discharged four days sooner than patients given placebo, though no criteria were given for determining improvement. Death rates were not significantly different. About 25% of patients receiving remdesivir had potentially severe side effects, including multiple organ dysfunction, septic shock, acute kidney injury and low blood pressure. Another 23% showed evidence on lab tests of liver damage.
|
|